Testing effectiveness (Phase 2)Study completedNCT00453895What this trial is testingSunitinib in Refractory Adrenocortical CarcinomaWho this might be right forAdrenocortical Carcinoma University of Wuerzburg 39
Testing effectiveness (Phase 2)Study completedNCT00831844What this trial is testingCixutumumab in Treating Patients With Relapsed or Refractory Solid TumorsWho this might be right forAdult RhabdomyosarcomaAdult Synovial SarcomaChildhood Hepatoblastoma+13 more National Cancer Institute (NCI) 116
Testing effectiveness (Phase 2)Active Not RecruitingNCT03333616What this trial is testingNivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsWho this might be right forGenitourinary CancerAdrenocortical CarcinomaNon-urothelial Bladder+5 more Dana-Farber Cancer Institute 100
Early research (Phase 1)Looking for participantsNCT04119024What this trial is testingGene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsWho this might be right forMetastatic Malignant Solid NeoplasmMetastatic MelanomaPathologic Stage IIIC Cutaneous Melanoma AJCC v8+14 more Anusha Kalbasi 18
Early research (Phase 1)Study completedNCT00020579What this trial is testingMS-275 in Treating Patients With Advanced Solid Tumors or LymphomaWho this might be right forCancer National Institutes of Health Clinical Center (CC) 75
Large-scale testing (Phase 3)Study completedNCT00538850What this trial is testingFentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainWho this might be right forCancer INSYS Therapeutics Inc 130
Early research (Phase 1)Study completedNCT01048892What this trial is testingSeneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine FeaturesWho this might be right forAdrenocortical CarcinomaGastrointestinal Carcinoid TumorKidney Cancer+3 more Children's Oncology Group 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT02867592What this trial is testingCabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare TumorsWho this might be right forAdrenal Cortical CarcinomaAlveolar Soft Part SarcomaCentral Nervous System Neoplasm+41 more National Cancer Institute (NCI) 109
Early research (Phase 1)Ended earlyNCT01832974What this trial is testingPossible New Therapy for Advanced CancerWho this might be right forAdrenocortical Carcinoma INSYS Therapeutics Inc 9